DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE; AC-203 1% Topical Ointment; AKST4290; ARAVA; Acetate; Apremilast; Avdoralimab; Avdoralimab (IPH5401); Azathioprine; Azathioprine or Mycophenolate mofetil; BIV009; Benralizumab; Bertilimumab; Blood test; CC; CC-10004; CORTANCYL 20 mg; Carboxymethylcellulose; Cellcept® in autoimmune bullous dermatoses; Cellulose; Clobetasol; Clobetasol 0.05% Topical Ointment; Clobetasol Propionate cream treatment; Clobetasol propionate; Clobetasol propionate + Methotrexate; Clobetasol propionate alone; Collagenase; Cortancyl; Cotton; Cultivated oral mucosal epithelial sheet transplantation; Cyclophosphamide; Cyclophosphamide 50Mg Oral Tablet; Cyclosporine; DERMOVAL; DF2156A; DUPILUMAB; Data report; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; Doxycycline; Dupilumab; Dupixent; Gold; Halometasone; INTERLEUKIN-2; IPH5401; Imatinib; Infliximab; Ixekizumab; Ladarixin; Leflunomide; MABTHERA; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Medrone; Mepolizumab; Mepolizumab (a-IL-5 antibody); Methotrexate; Methylprednisolone; Minocycline; Mometasone; Mometasone furoate; Mycophenolate; Mycophenolate mofetil; Myfortic; Myfortic 180 mg; Myfortic 180 mg Filmtabletten; NNC0215-0384; NPB-01; Nicotinamide; Omalizumab; Oral corticosteroids (OCS); Otezla; Other: Blood sample and cotton skin swabs; Other: Control; PREDNISONE; Petrolatum; Prednisolone; Prednisone; Procedure: Clobetasol propionate; Procedure: Impedance analysis; Procedure: bone densitometry; Procedure: collagenase; Procedure: radiographs of the thoracic and lumbar spine; QGE031; RESTASIS; RITUXIMAB; RVA576; Riboflavin; Rituximab; Rituximab 1g IV; Rituximab combined with Omalizumab; SIMVASTATIN; Silver; Simvastatin; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; Solu-Medrone; Tildrakizumab; Tildrakizumab Prefilled Syringe; Topical infliximab; Treatment systemic therapy (prednisone); Treatment with systemic therapy (doxycycline); Treatment with systemic therapy (methotrexate); Treatment with systemic therapy (prednisone); Treatment with topical superpotent corticosteroid therapy; Tripterygium; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000029007	2020-01-01	2020-01-11	Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid	Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid	Bullous Pemphigoid	experimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream;	The First Affiliated Hospital of Kunming Medical University	NULL	Recruiting			Both	experimental group:30;control group:30;	Phase 4	China
2	ChiCTR-IOR-15007146	2009-10-01	2015-09-17	Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoid	Efficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trial	bullous pemphigoid	Control Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids;	Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine	NULL	Completed			Both	Control Group (C):40;Treatment Group (T):40;		China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000029007

2020-01-01

2020-01-11

Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid

Bullous Pemphigoid

experimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream;

The First Affiliated Hospital of Kunming Medical University

NULL

Recruiting

Both

experimental group:30;control group:30;

Phase 4

China

ChiCTR-IOR-15007146

2009-10-01

2015-09-17

Combined treatment with low dose systemic steroids andtopical steroids in bullous pemphigoid andfactors of treatment-refractory bullous pemphigoid

Efficacy of low dose systemic steroids combined with topical steroids in the treatment of bullous pemphigoid andrisk factors for treatment-refractory patients:A Randomized Controlled Trial

bullous pemphigoid

Control Group (C):apply 0.05% halometasone cream daily;Treatment Group (T):apply 0.05% halometasone cream daily+low-dose systemic steroids;

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

NULL

Completed

Both

Control Group (C):40;Treatment Group (T):40;

China